Extrait

Background and study aims Despite progress in early detection and treatment for many cancers, ovarian cancer (OC) remains a leading cause of cancer death in women. The absence of a distinct ‘pre-cancerous’ stage combined with non-specific symptoms such as bloating and back pain makes timely detection challenging. A novel research programme (PROMISE, jointly funded by CRUK and The Eve Appeal) is currently under way to test whether a ‘personalized’ approach to ovarian cancer screening (which includes assessment of genetic risk markers alongside biomarkers and epidemiological data) could improve current risk prediction approaches; making population-based screening for ovarian cancer feasible. One important aspect of the research is to discover how to best convey the potential benefits and risks of the programme to women to help them make an informed decision about participating in the PROMISE programme. Who can participate? All women aged 18-74 who are able to give informed consent and who have not been diagnosed with ovarian cancer What does the study involve? The study is run over the Internet. Participants are randomly allocated into one of two groups and are asked to visit one of two versions of the website informing about PROMISE. Here, they find information about ovarian cancer, genetic testing and PROMISE. Participants are instructed to browse the website at their leisure, and to make a hypothetical decision whether or not they'd like to take part in PROMISE. Participants are asked questions about ovarian cancer and genetic testing before and after visiting the website. They are also asked about their thoughts and feelings about taking part in PROMISE after they visited the website. What are the possible benefits and risks of participating? Participants will get information about ovarian cancer and its symptoms. Participants will also learn about potential benefits and harms of ovarian cancer screening. This may be helpful in current and future related health decision making. In addition, we will refer participants to trusted sources to find out further information should they wish to do so (e.g. CRUK; The Eve Appeal, Ovacome). Thinking about cancer may be upsetting for some people. We will provide full information about ovarian cancer at the end of the study and refer participants to trusted sources to find out further information should they wish to do so (e.g. CRUK; Eve Appeal, Ovacome) Where is the study run from? The Health Behaviour Research Centre, University College London, London (UK) When is the study starting and how long is it expected to run for? April 2015 to September 2016. Who is funding the study? The study is jointly funded by Cancer Research UK and The Eve Appeal Who is the main contact? Dr Susanne Meisel [email protected]

Critère d'inclusion

• Intentions to take part in personalized risk-stratified ovarian cancer screening

Liens

• ictrp
• isrctn